The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
W F De Azevedo; H J Mueller-Dieckmann; U Schulze-Gahmen; P J Worland; E Sausville; S H Kim (Profiled Author: Edward A Sausville)
Deartment of Chemistry, University of California, Berkeley, 94720, USA.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(7):2735-40.
The central role of cyclin-dependent kinases (CDKs) in cell cycle regulation makes them a promising target for studying inhibitory molecules that can modify the degree of cell proliferation. The discovery of specific inhibitors of CDKs such as polyhydroxylated flavones has opened the way to investigation and design of antimitotic compounds. A novel flavone, (-)-cis-5,7-dihydroxyphenyl-8-[4-(3-hydroxy-1-methyl)piperidinyl] -4H-1-benzopyran-4-one hydrochloride hemihydrate (L868276), is a potent inhibitor of CDKs. A chlorinated form, flavopiridol, is currently in phase I clinical trials as a drug against breast tumors. We determined the crystal structure of a complex between CDK2 and L868276 at 2.33 angstroms resolution and refined to an Rfactor 20.3%. The aromatic portion of the inhibitor binds to the adenine-binding pocket of CDK2, and the position of the phenyl group of the inhibitor enables the inhibitor to make contacts with the enzyme not observed in the ATP complex structure. The analysis of the position of this phenyl ring not only explains the great differences of kinase inhibition among the flavonoid inhibitors but also explains the specificity of L868276 to inhibit CDK2 and CDC2.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
B A Carlson; M M Dubay; E A Sausville; L Brizuela; P J WorlandCancer research 1996;56(13):2973-8.
V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S GutkindThe Journal of clinical investigation 1998;102(9):1674-81.
B Carlson; T Lahusen; S Singh; A Loaiza-Perez; P J Worland; R Pestell; C Albanese; E A Sausville; A M SenderowiczCancer research 1999;59(18):4634-41.
Appears in this Publication
Author of this Publication